ELEVAR THERAPEUTICS ANNOUNCES FDA PDUFA DATE FOR RESUBMITTED NEW DRUG APPLICATION FOR RIVOCERANIB IN COMBINATION WITH CAMRELIZUMAB FOR USE AS A FIRST-LINE SYSTEMIC TREATMENT FOR UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA

Reuters · 1d ago

Please log in to view news